These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7927807)

  • 41. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.
    van de Verg LL; Mallett CP; Collins HH; Larsen T; Hammack C; Hale TL
    Infect Immun; 1995 May; 63(5):1947-54. PubMed ID: 7729907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
    Price GA; Russell MW; Cornelissen CN
    Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined parenteral and oral immunization results in an enhanced mucosal immunoglobulin A response to Shigella flexneri.
    Keren DF; McDonald RA; Carey JL
    Infect Immun; 1988 Apr; 56(4):910-5. PubMed ID: 3278985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a.
    Liu Q; Su H; Bian X; Wang S; Kong Q
    Int J Med Microbiol; 2020 Jul; 310(5):151427. PubMed ID: 32654768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.
    Hartman AB; Van de Verg LL; Mainhart CR; Tall BD; Smith-Gill SJ
    Clin Diagn Lab Immunol; 1996 Sep; 3(5):584-9. PubMed ID: 8877140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.
    Kotloff KL; Losonsky GA; Nataro JP; Wasserman SS; Hale TL; Taylor DN; Newland JW; Sadoff JC; Formal SB; Levine MM
    Vaccine; 1995 Apr; 13(5):495-502. PubMed ID: 7639017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition.
    Mukhopadhaya A; Mahalanabis D; Khanam J; Chakrabarti MK
    Vaccine; 2003 Jun; 21(21-22):3043-50. PubMed ID: 12798648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.
    Kotloff KL; Herrington DA; Hale TL; Newland JW; Van De Verg L; Cogan JP; Snoy PJ; Sadoff JC; Formal SB; Levine MM
    Infect Immun; 1992 Jun; 60(6):2218-24. PubMed ID: 1587589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a.
    Baron LS; Kopecko DJ; Formal SB; Seid R; Guerry P; Powell C
    Infect Immun; 1987 Nov; 55(11):2797-801. PubMed ID: 3312013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a.
    Way SS; Borczuk AC; Goldberg MB
    Infect Immun; 1999 Aug; 67(8):3970-9. PubMed ID: 10417163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral immunization of mice with a live recombinant Yersinia enterocolitica O:9 strain that produces the cholera toxin B subunit.
    Sory MP; Hermand P; Vaerman JP; Cornelis GR
    Infect Immun; 1990 Aug; 58(8):2420-8. PubMed ID: 2370100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.
    Apter FM; Michetti P; Winner LS; Mack JA; Mekalanos JJ; Neutra MR
    Infect Immun; 1993 Dec; 61(12):5279-85. PubMed ID: 8225601
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
    Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E
    Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strategy for cross-protection among Shigella flexneri serotypes.
    Noriega FR; Liao FM; Maneval DR; Ren S; Formal SB; Levine MM
    Infect Immun; 1999 Feb; 67(2):782-8. PubMed ID: 9916090
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monoclonal antibodies specific for Shigella flexneri lipopolysaccharides: clones binding to type IV, V, and VI antigens, group 3,4 antigen, and an epitope common to all Shigella flexneri and Shigella dysenteriae type 1 stains.
    Carlin NI; Lindberg AA
    Infect Immun; 1987 Jun; 55(6):1412-20. PubMed ID: 2437036
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Field trials with an oral cell-free vaccine made from Shigella flexneri].
    Sergeev VV; Kreĭnin LS; Elkina SI; Kaverina KG; Levina LA
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Oct; (10):54-9. PubMed ID: 2692352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.
    Lin J; Smith MA; Benjamin WH; Kaminski RW; Wenzel H; Nahm MH
    Clin Vaccine Immunol; 2016 Aug; 23(8):681-8. PubMed ID: 27280622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An auxotrophic live oral Shigella flexneri vaccine: development and testing.
    Kärnell A; Stocker BA; Katakura S; Sweiha H; Reinholt FP; Cam PD; Trach DD; Lindberg AA
    Rev Infect Dis; 1991; 13 Suppl 4():S357-61. PubMed ID: 2047663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serotype conversion of a Shigella flexneri candidate vaccine strain via a novel site-specific chromosome-integration system.
    Guan S; Verma NK
    FEMS Microbiol Lett; 1998 Sep; 166(1):79-87. PubMed ID: 9741086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.